ECO Animal Health Group
EAH · AIM · Health Care · mcap £64m · 95.5p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 17 Sep 26 | USDA-CVB approves ECOVAXXIN® MS field safety data
USDA-CVB approves field safety data for ECOVAXXIN® MS poultry vaccine, advancing towards US marketing authorisation. |
+1.6% | |
| 11 Sep 26 | Share Awards to Executive Directors
Share options and restricted share units granted to CEO and CFO under Long Term Incentive Plan. |
−6.8% | |
| 08 Sep 26 | Board change | Didier Branellec appointed Non-Executive Director
Dr. Didier Branellec appointed as Independent Non-Executive Director, effective immediately. |
+1.5% |
| 19 Aug 26 | Board change | CEO and CFO Exercise of Options and RPT
CEO and CFO Exercise of Share Options and Director/PDMR Shareholdings |
+0.0% |
| 12 Aug 26 | Exclusive in-licensing agreement with Vaxinano
ECO signs exclusive perpetual licence for Vaxinano's sheep toxoplasmosis vaccine candidate worldwide. |
+5.7% | |
| 15 Jul 26 | Results | Results for the year ended 31 March 2026
FY26 revenue grew 10% to £87.5m with adjusted EBITDA up 16% to £8.5m, ahead of expectations. |
+2.9% |
| 02 Jul 26 | EU launch of ECOVAXXIN® MS
ECOVAXXIN® MS, first product from proprietary pipeline, launched commercially across EU. |
+3.2% | |
| 04 Jun 26 | Renewal of revolving credit facility
Renewed £10m revolving credit facility with NatWest on improved terms until June 2031. |
+0.0% | |
| 14 Apr 26 | Appointment of Head of Business Development
Dr Andrew Winder appointed Head of Business Development to identify strategic growth opportunities for R&D pipeline. |
+5.3% | |
| 31 Mar 26 | Board change | Directorate Change
Independent Non-Executive Director Frank Armstrong to step down following the AGM in September 2026. |
−1.5% |
| 19 Mar 26 | Trading update | Full Year Trading Update
FY26 revenue up c.8% to c.£85.8m with materially improved margins and adjusted EBITDA ahead of expectations. |
+6.2% |
| 11 Mar 26 | ECOVAXXIN® MG favourable USDA safety assessment
USDA delivers favourable safety assessment for ECOVAXXIN® MG poultry vaccine, clearing path to US marketing authorisation. |
+4.2% | |
| 26 Feb 26 | EU launch plans for ECOVAXXIN® MS
EU marketing authorisation granted for ECOVAXXIN® MS poultry vaccine; phased launch planned 2026-2027. |
+4.9% | |
| 22 Dec 25 | ECOVAXXIN® MS EU marketing authorisation granted
European Commission grants marketing authorisation for ECOVAXXIN MS poultry vaccine against Mycoplasma synoviae. |
+6.2% | |
| 18 Dec 25 | Exercise of Share Options by Director
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that Christopher Wilks, Chief Fin |
−4.2% | |
| 01 Dec 25 | Results | Results for the six months ended 30 September 2025
H1 2025 revenue £39.4m up 19%, adjusted EBITDA £3.0m, ahead of guidance; EMA Positive Opinion for ECOVAXXIN® MS poultry vaccine. |
+4.3% |
| 10 Nov 25 | EMA Positive Opinion Received for ECOVAXXIN® MS
EMA Committee recommends marketing approval for poultry vaccine ECOVAXXIN MS, with commercial launch expected H2 2026. |
+7.4% |
Company filings. Not investment advice.